Corporate News
Dermata Therapeutics (ticker DRMA) experienced a sharp decline in its share price during the 24‑hour trading window that closed at 01:53 PM Central Europe on Thursday, 22 September 2026. The stock fell 8.05 %, settling around USD 0.80 on the principal exchanges. With an outstanding supply of 5 million shares, the company’s market capitalization sits at approximately USD 4 million, while only USD 177 000 worth of shares changed hands in the preceding 24 hours. The downward trend has accelerated since the end of August, with a cumulative decline of 30.43 % over the last month.
The 200‑day simple moving average, a widely watched technical indicator, stands at USD 1.36, underscoring the current valuation gap. Historically, the stock reached its all‑time high of USD 4.66 on 26 January 2026 and its 52‑week low of USD 0.60 on 14 October 2026, indicating a highly volatile trajectory.
Recent Filing
Dermata Therapeutics recently filed a 424(b)(3) prospectus, which discloses a planned resale of up to approximately 6.9 million shares of its common stock. These shares include existing holdings and those that may be issued upon exercise of pre‑funded Series E, Series F, and bank warrants issued during a private placement that closed in mid‑August. Importantly, the company will not receive proceeds from the sale of the shares themselves; instead, it will receive cash from any warrant exercises. This inflow of capital is earmarked for working capital and general corporate purposes.
The filing also outlines the rights and limitations of the selling shareholders, including potential ownership caps tied to warrant exercise. It further notes that the company has entered into a registration‑rights agreement to streamline the resale of these securities. The prospectus reflects Dermata’s ongoing shift toward a direct‑to‑consumer skincare platform, following the launch of its first product, the Tome Foundational Treatment, in late August.
Market Context
The broader market environment has seen mixed movements. In the past 24 hours, several comparable stocks exhibited the following performance:
| Company | Ticker | Performance | Current Price | Market Cap |
|---|---|---|---|---|
| Excalibur Metals | EXCL.V | –4.76 % | CAD 0.10 | CAD 6.4 million |
| Ambow Education | AMBO | –2.92 % | USD 1.56 | USD 4.6 million |
| Bioaffinity | BIAF | –2.46 % | USD 3.57 | USD 4.7 million |
| Xenetic Biosciences | XBIO | +1 % | USD 2.02 | USD 4.7 million |
| –Diagnostics | CODX | –0.77 % | USD 0.64 | USD 4.5 million |
While the overall sector shows modest volatility, Dermata’s pronounced decline stands out, suggesting heightened investor concern or a reaction to recent regulatory filings.
Company Overview
Dermata Therapeutics, Inc. is a clinical‑stage biopharmaceutical company focused on treating medical and aesthetic skin conditions. The firm operates on a global scale, offering a portfolio of products aimed at improving skin health and appearance. Listed on Nasdaq under the symbol DRMA, the company is actively developing a direct‑to‑consumer skincare platform that leverages its clinical expertise and product pipeline.
For further details about Dermata’s therapeutic approach, product pipeline, and corporate developments, prospective investors and stakeholders may visit the company’s website at www.dermatarx.com .
